Evidence map›Paper›PMID 15020310›Full record

Trial reportAnnals of the rheumatic diseases2004

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

H Tannenbaum, F Berenbaum, J-Y Reginster, J Zacher, J Robinson, G Poor, H Bliddal, D Uebelhart, S Adami, F Navarro and 3 more

Open access · bronzeAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 10 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 10 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Celecoxib for osteoarthritis.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Efficacy of celecoxib for pain management after arthroscopic surgery of hip: a prospective randomized placebo-controlled study.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2014
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Lumiracoxib.Drugs · 2004
    Trial
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 10 countries.

H TannenbaumRheumatic Disease Centre of Montreal, 4060 SteCatherine St West, Suite 740, Montreal H3Z 2Z3 QC, Canada. htann@attglobal.net
F Berenbaum
J-Y Reginster
J Zacher
J Robinson
G Poor
H Bliddal
D Uebelhart
S Adami
F Navarro
A Lee
A Moore
A Gimona
Novartis (Switzerland) · CHAltoona Arthritis and Osteoporosis Center · USCentre Hospitalier Universitaire de Liège · BEFrederiksberg Hospital · DKHEC Montréal · CAHelios Kliniken · DEHospital Universitario Virgen Macarena · ESOrszágos Reumatológiai és Fizioterápiás Intézet · HUSorbonne Université · FRSynexus (United Kingdom) · GBUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study.

methodsAfter a 37 day washout period for nonsteroidal antiinflammatory drugs, 1702 patients with knee OA were randomised to lumiracoxib 200 or 400 mg once daily od, celecoxib 200 mg od, or placebo 2221. A visual analogue scale VAS pain intensity > or =40 mm was required. Primary efficacy variables were OA pain intensity VAS mm in the target knee, patients global assessment of disease activity VAS mm, and WOMAC pain subscale and total scores at 13 weeks. OA pain intensity, patients and physicians global assessment of disease activity, and WOMAC total and all subscale scores were analysed by visit as secondary variables.

resultsLumiracoxib showed significant improvements in all primary and secondary variables compared with placebo. Lumiracoxib 200 mg od and celecoxib 200 mg od achieved similar improvements in OA pain intensity and functional status. Lumiracoxib 400 mg od demonstrated better efficacy for OA pain intensity and patients global assessment of disease activity at weeks 2, 4, and 8 and similar efficacy at week 13 compared with celecoxib 200 mg od. The incidence of adverse events AEs, serious AEs, and discontinuations due to AEs was similar in each group.

conclusionLumiracoxib demonstrated significant improvement in OA pain intensity, patients global assessment of disease activity, and the WOMAC pain subscale and total scores compared with placebo. Lumiracoxib was well tolerated in this study, with overall tolerability similar to that of placebo and celecoxib.

Indexed as

AdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacDouble-Blind MethodDrug Administration ScheduleFemaleHumansIsoenzymesLogistic ModelsMaleAnti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacIsoenzymeslumiracoxibMembrane ProteinsOrganic ChemicalsProstaglandin-Endoperoxide SynthasesPTGS2 protein, humanPyrazolesSulfonamides

Identifiers

PMID15020310
PMCPMC1754793
OpenAlexW2164323898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.